Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Sponsor:

Mayo Clinic

Code:

NCT03017820

Conditions

B-Cell Non-Hodgkin Lymphoma

Histiocytic and Dendritic Cell Neoplasm

Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Cyclophosphamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information